Fennec Pharmaceuticals (FENC) Accumulated Expenses (2010 - 2025)

Fennec Pharmaceuticals' Accumulated Expenses history runs 16 years deep, the most recent figure standing at $5.6 million for Q4 2025.

• Quarterly Accumulated Expenses rose 64.38% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.6 million (up 64.38% YoY) and the FY2025 annual result came in at $5.6 million, up 64.38% from the prior year.
• Accumulated Expenses was $5.6 million for Q4 2025 at Fennec Pharmaceuticals, up from $1.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $5.6 million in Q4 2025 and bottomed at $171000.0 in Q2 2021.
• A 5-year average of $1.5 million and a median of $1.0 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses plunged 70.35% — and 2023, when it soared 1343.85%.
• Fennec Pharmaceuticals' Accumulated Expenses stood at $877000.0 in 2021, then plunged by 70.35% to $260000.0 in 2022, then surged by 1343.85% to $3.8 million in 2023, then slipped by 8.68% to $3.4 million in 2024, then jumped by 64.38% to $5.6 million in 2025.
• Business Quant data shows FENC's Accumulated Expenses at $5.6 million in Q4 2025, $1.3 million in Q3 2025, and $1.3 million in Q2 2025.